scholarly journals A Two-Stage Hepatectomy Procedure Combined With Portal Vein Embolization to Achieve Curative Resection for Initially Unresectable Multiple and Bilobar Colorectal Liver Metastases

2004 ◽  
Vol 240 (6) ◽  
pp. 1037-1051 ◽  
Author(s):  
Daniel Jaeck ◽  
Elie Oussoultzoglou ◽  
Edoardo Rosso ◽  
Michel Greget ◽  
Jean-Christophe Weber ◽  
...  
2003 ◽  
Vol 185 (3) ◽  
pp. 221-229 ◽  
Author(s):  
Daniel Jaeck ◽  
Philippe Bachellier ◽  
Hiroshi Nakano ◽  
Elie Oussoultzoglou ◽  
Jean-Christophe Weber ◽  
...  

2011 ◽  
Vol 16 (3) ◽  
pp. 554-561 ◽  
Author(s):  
Masato Narita ◽  
Elie Oussoultzoglou ◽  
Marie-Pierre Chenard ◽  
Pascal Fuchshuber ◽  
Edoardo Rosso ◽  
...  

Surgery Today ◽  
2014 ◽  
Vol 45 (4) ◽  
pp. 511-516
Author(s):  
Suguru Yamashita ◽  
Kiyoshi Hasegawa ◽  
Michiro Takahashi ◽  
Junichi Arita ◽  
Yoshihiro Sakamoto ◽  
...  

Cancers ◽  
2021 ◽  
Vol 13 (2) ◽  
pp. 200
Author(s):  
Salah Khayat ◽  
Gianluca Cassese ◽  
François Quenet ◽  
Christophe Cassinotto ◽  
Eric Assenat ◽  
...  

Colorectal liver metastases (CRLM) are the major cause of death in patients with colorectal cancer (CRC). The cornerstone treatment of CRLM is surgical resection. Post-operative morbidity and mortality are mainly linked to an inadequate future liver remnant (FLR). Nowadays preoperative portal vein embolization (PVE) is the most widely performed technique to increase the size of the future liver remnant (FLR) before major hepatectomies. One method recently proposed to increase the FLR is liver venous deprivation (LVD), but its oncological impact is still unknown. The aim of this study is to report first short- and long-term oncological outcomes after LVD in patients undergoing right (or extended right) hepatectomy for CRLM. Seventeen consecutive patients undergoing LVD between July 2015 and May 2020 before an (extended) right hepatectomy were retrospectively analyzed from an institutional database. Post-operative and follow-up data were analyzed and reported. Primary outcomes were 1-year and 3-year overall survival (OS) and hepatic recurrence (HR). Postoperative complications occurred in 8 patients (47%). No deaths occurred after surgery. HR occurred in 9 patients (52.9%). 1-year and 3-year OS were 87% (95% confidence interval [CI]: ±16%) and 60.3%, respectively (95% CI: ±23%). Median Disease-Free Survival (DFS) was 6 months (CI 95%: 4.7–7.2). With all the limitations of a retrospective study with a small sample size, LVD showed similar oncological outcomes compared to literature reports for Portal Vein Embolization (PVE).


In Vivo ◽  
2020 ◽  
Vol 34 (5) ◽  
pp. 2919-2925
Author(s):  
VLADISLAV TRESKA ◽  
JAN BRUHA ◽  
VACLAV LISKA ◽  
JAKUB FICHTL ◽  
KRISTYNA PROCHAZKOVA ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document